Acknowledgement
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HI10C2020) and Biosensors Inc.
References
- Park DW, Park SW. Stent thrombosis in the era of the drug-eluting stent. Korean Circ J 2005;35:791-4. https://doi.org/10.4070/kcj.2005.35.11.791
- Minha S, Barbash IM, Dvir D, et al. Second-generation everolimus-eluting stents compared to first-generation drug-eluting stents in patients treated for multivessel disease. J Interv Cardiol 2013;26:561-9. https://doi.org/10.1111/joic.12063
- Grundeken MJ, Wykrzykowska JJ, Ishibashi Y, et al. First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial. Catheter Cardiovasc Interv 2016;87:E248-60. https://doi.org/10.1002/ccd.26344
- Vlachojannis GJ, Smits PC, Hofma SH, et al. Biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: final 5-year report from the COMPARE II trial (abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent). JACC Cardiovasc Interv 2017;10:1215-21. https://doi.org/10.1016/j.jcin.2017.02.029
- Im E, Kim GS, Shin DH, et al. Long-term clinical outcomes of a biodegradable polymer-based biolimus-eluting stent. J Interv Cardiol 2016;29:162-7. https://doi.org/10.1111/joic.12283
- Cavalcante R, Sotomi Y, Mancone M, et al. Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. Eur Heart J 2017;38:1969-77. https://doi.org/10.1093/eurheartj/ehx138
- Hausleiter J, Kastrati A, Mehilli J, et al. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial. Am Heart J 2003;146:882-6. https://doi.org/10.1016/S0002-8703(03)00435-6
- Lee DH, Park TK, Song YB, et al. Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents. PLoS One 2017;12:e0183079. https://doi.org/10.1371/journal.pone.0183079
- Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51. https://doi.org/10.1161/CIRCULATIONAHA.106.685313
- Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011;42:1-28.
- Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014;33:1242-58. https://doi.org/10.1002/sim.5984
- Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013;381:651-60. https://doi.org/10.1016/S0140-6736(12)61852-2
- Kaiser C, Galatius S, Jeger R, et al. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation 2015;131:74-81. https://doi.org/10.1161/CIRCULATIONAHA.114.013520
- Bangalore S, Toklu B, Amoroso N, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ 2013;347:f6625. https://doi.org/10.1136/bmj.f6625
- Navarese EP, Tandjung K, Claessen B, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ 2013;347:f6530. https://doi.org/10.1136/bmj.f6530
- Kang SH, Park KW, Kang DY, et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J 2014;35:1147-58. https://doi.org/10.1093/eurheartj/eht570
- Sakurai R, Burazor I, Bonneau HN, Kaneda H. Long-term outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents: a meta-analysis of randomized controlled trials. Int J Cardiol 2016;223:1066-71. https://doi.org/10.1016/j.ijcard.2016.07.078
- Grube E, Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices 2006;3:731-41. https://doi.org/10.1586/17434440.3.6.731
- Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41:1283-8. https://doi.org/10.1016/S0735-1097(03)00119-0
- Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011;123:1400-9. https://doi.org/10.1161/CIRCULATIONAHA.110.003210
- Sim DS, Jeong MH, Park DS, et al. Effect of pretreatment of ezetimibe/simvastatin on arterial healing and endothelialization after drug-eluting stent implantation in a porcine coronary restenosis model. Korean Circ J 2015;45:110-6. https://doi.org/10.4070/kcj.2015.45.2.110
- Giustino G, Baber U, Aquino M, et al. Safety and efficacy of new-generation drug-eluting stents in women undergoing complex percutaneous coronary artery revascularization: from the win-des collaborative patient-level pooled analysis. JACC Cardiovasc Interv 2016;9:674-84. https://doi.org/10.1016/j.jcin.2015.12.013
- Migliorini A, Valenti R, Parodi G, et al. Angiographic and clinical outcomes after everolimus-eluting stenting for unprotected left main disease and high anatomic coronary complexity. JACC Cardiovasc Interv 2016;9:1001-7. https://doi.org/10.1016/j.jcin.2016.02.016
- Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505-13. https://doi.org/10.1161/CIRCULATIONAHA.111.059022
Cited by
- Long-Term Outcomes of Biodegradable Versus Second-Generation Durable Polymer Drug-Eluting Stent Implantations for Myocardial Infarction vol.13, pp.1, 2019, https://doi.org/10.1016/j.jcin.2019.08.020
- Histopathologic and physiologic effect of bifurcation stenting: current status and future prospects vol.17, pp.3, 2019, https://doi.org/10.1080/17434440.2020.1733410
- Clopidogrel monotherapy in patients with and without on-treatment high platelet reactivity: a SMART-CHOICE substudy vol.17, pp.11, 2019, https://doi.org/10.4244/eij-d-21-00223